Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0092
Research
Nav-Gal
Senolytic / β-gal prodrug
Targeted senolytic with reduced systemic platelet toxicity concept
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Senolytic prodrug
- Primary mechanism
- Galacto-conjugated navitoclax activated by senescence-associated β-galactosidase
- Primary market use
- Senolytic research
Pharmacology
- Molecular weight (Da)
- Not consistently disclosed
- Oral bioavailability
- N/A; preclinical prodrug
- Half-life
- ~1–12 h provisional PK estimate
- Route tags
- Route-dependent / verify
- Evidence level
- Preclinical
- Clinical status
- Research
- Value-for-money score
- 5 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Preclinical strategy to improve navitoclax selectivity; no established human PK